Basecamp Research raises $140m in a Series C round led by S32 to advance its genetic models.
The financing values the biotechnology company at $800m and will support its in vivo cell therapy pipeline.
≈ £106M at $1 = £0.7570 on 24 Sep 2026
Basecamp Research builds biological foundation models on proprietary genetic datasets to engineer in vivo cell therapies.
London-based biotechnology company Basecamp Research has secured $140m in a Series C funding round that pushes its valuation to $800m. The oversubscribed financing was led by S32 and drew participation from an array of new and existing backers, including Nvidia, Singular, True Ventures, and the NATO Innovation Fund. Basecamp will direct the capital toward training its EDEN biological foundation models and developing in vivo cell therapies designed to edit DNA directly within patients.
From the founder
"We believe the future of medicine lies in reprogramming the body to repair itsel. We design the models and the medicines to teach it howf"
Glen Gowers
Chief Executive at Basecamp Research
Investor perspective
"how we understand disease, discover medicines and ultimately improve and extend people's lives."
Andy Conrad
General Partner, S32
Use of funds
- 01Fund research and development
Investors
Andy Conrad
S32
Anthropic
NVIDIA
NATO Innovation Fund
Singular
True Ventures
Menlo Ventures
Catalio Capital Management
European Tech Collective
Firebrand River Capital
Inception Fund
King Philanthropies
PostScriptum
Redalpine
Rockefeller Foundation
Sovereign AI